Award
NIH Reporter #1R21CA318322-01
Combining alpha-Particle Radioimmunotherapy and Antibody–Drug Conjugates to Improve Outcomes in Pancreatic Cancer
Recipient
National Cancer Institute (NCI), part of the NIH
Award Amount
$420,943.00
Ceiling
$420,943.00
Awarded
August 06, 2026
Identifier
1R21CA318322-01
Award for research combining alpha-particle radioimmunotherapy and antibody-drug conjugates to improve pancreatic cancer outcomes.
Description
This project aims to evaluate a tumor-targeted strategy using alpha-particle radioimmunotherapy combined with antibody-drug conjugates to improve outcomes in pancreatic cancer. The award is part of NIH's mission to reduce cancer morbidity and mortality.